Defining the clinical course of multiple sclerosis: the 2013 révisions, Neurology, vol.83, pp.278-286, 2014. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, pp.1444-1452, 1983. ,
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study, Ann Neurol, vol.56, pp.303-306, 2004. ,
Benign multiple sclerosis: does it exist?, Curr Neurol Neurosci Rep, vol.12, pp.601-609, 2012. ,
Longitudinal follow-up of "benign" multiple sclerosis at 20 years, Neurology, vol.68, pp.496-500, 2007. ,
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome, Brain, vol.114, pp.1045-1056, 1991. ,
Age at disability milestones in multiple sclerosis, Brain, vol.129, pp.595-605, 2006. ,
Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, pp.916-921, 2008. ,
Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capturerecapture method, Mult Scler Houndmills Basingstoke Engl, vol.18, pp.1244-1250, 2012. ,
EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.55, pp.671-676, 1992. ,
New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, pp.227-231, 1983. ,
Recommended diagnostic criteria for MS: Guidelines from the international panel on the diagnosis of MS, Ann Neurol, vol.50, pp.121-127, 2001. ,
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Ann Neurol, vol.58, pp.840-846, 2005. ,
Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study, Mult Scler, vol.19, pp.458-465, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00878705
Benign course in multiple sclerosis: a review, Acta Neurol Scand, vol.113, pp.359-369, 2006. ,
Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients, Mult Scler, vol.15, pp.251-257, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02307061
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, pp.899-910, 2006. ,
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, pp.387-401, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617764
Long-term follow-up of clinical trials of multiple sclerosis therapies, Neurology, vol.76, pp.26-34, 2011. ,
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, vol.343, pp.898-904, 2000. ,
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006. ,
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, vol.58, pp.169-178, 2002. ,
Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors, J Neurol Neurosurg Psychiatry, vol.67, pp.148-152, 1999. ,
Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway, Mult Scler, vol.15, pp.942-950, 2009. ,
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC), BMC Neurol, vol.16, p.102, 2016. ,
Benign multiple sclerosis, Acta Neurol Scand Suppl, pp.55-57, 2006. ,
The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study, Neurology, vol.14, pp.919-921, 2004. ,
Benign multiple sclerosis: a new definition of this entity is needed, Mult Scler, vol.18, pp.210-218, 2012. ,
The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis, Mult Scler, vol.17, pp.1375-1383, 2011. ,
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group, Lancet, vol.353, pp.964-969, 1999. ,
More severe disability of North Africans vs Europeans with multiple sclerosis in France, Neurology, vol.68, pp.29-32, 2007. ,
, les proportions des patients « bénins » atteints de SEP devraient accroître, sous réserve de l'applicabilité de ces thérapeutiques à long terme et en l'absence d'effet indésirable. RÉFÉRENCES BIBLIOGRAPHIQUES
New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, issue.3, pp.227-231, 1983. ,
Recommended diagnostic criteria for MS: Guidelines from the international panel on the diagnosis of MS, Ann Neurol, vol.50, issue.1, pp.121-127, 2001. ,
Clinical viral infections and multiple sclerosis, Lancet, vol.1, issue.8441, pp.1313-1318, 1985. ,
Environmental factors and multiple sclerosis, Lancet Neurol, vol.7, issue.3, pp.268-77, 2008. ,
Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, issue.9, pp.916-937, 2008. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983. ,
Benign multiple sclerosis: a need for a consensus, Acta Neurol Scand Suppl, issue.190, pp.44-50, 2010. ,
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis, Lancet Neurol, vol.4, issue.5, pp.281-289, 2005. ,
Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients, Mult Scler, vol.15, issue.2, pp.251-258, 2009. ,
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain, vol.126, issue.4, pp.770-82, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00427394
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC), BMC Neurol, vol.16, p.102, 2016. ,
Brain and spinal cord MR in benign multiple sclerosis: a follow-up study, J Neurol Sci, vol.143, issue.1-2, pp.143-152, 1996. ,
MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype, Neurology, vol.12, pp.1693-701, 2009. ,
Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging, Magn Reson Imaging, vol.17, issue.5, pp.653-61, 1999. ,
A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis, Arch Neurol, vol.65, issue.9, pp.1223-1253, 2008. ,
Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis, Clin Immunol, vol.150, issue.1, pp.109-129, 2014. ,
Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis, PLoS One, vol.7, issue.10, p.46871, 2012. ,
Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration, Eur J Radiol, vol.82, issue.12, pp.848-52, 2013. ,
Low degree of cortical pathology is associated with benign course of multiple sclerosis, Mult Scler, vol.19, issue.7, pp.904-915, 2013. ,
Gray matter atrophy is related to long-term disability in multiple sclerosis, Ann Neurol, vol.64, issue.3, pp.247-54, 2008. ,
Magnetic resonance evidence of cortical onset of multiple sclerosis, Mult Scler, vol.15, issue.8, pp.933-974, 2009. ,
Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance, Arch Neurol, vol.69, issue.2, pp.183-90, 2012. ,
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, vol.8, issue.11, pp.987-97, 2009. ,
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006. ,
Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study, Mult Scler, vol.19, issue.4, pp.458-65, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00878705
Cognitive impairment in multiple sclerosis, Lancet Neurol, vol.7, issue.12, pp.1139-51, 2008. ,
Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors, Mult Scler, vol.6, issue.2, pp.124-154, 2000. ,
The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study, Neurology, issue.5, pp.919-940, 2004. ,
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, CHAMPS Study Group, vol.343, issue.13, pp.898-904, 2000. ,
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006. ,
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, vol.58, issue.2, pp.169-78, 2002. ,
Treatment optimization in MS: Canadian MS Working Group updated recommendations, Can J Neurol Sci, vol.40, issue.3, pp.307-330, 2013. ,
OAS1: a multiple sclerosis susceptibility gene that influences disease severity, Neurology, vol.3, issue.5, pp.411-419, 2010. ,
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis, Lancet, vol.14, issue.9374, pp.2036-2079, 2003. ,
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis, Lancet Neurol, vol.4, issue.5, pp.281-289, 2005. ,
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up, Brain, vol.121, issue.3, p.495, 1998. ,